Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000352167

Medchemexpress LLC Pcc0208017 | 2623158-64-3 | 99.5% | 403.40 | 50 MG
SDP

Catalog No. 5000352167
Encompass_Preferred

PCC0208017 is a potent microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. It suppresses glioma progression both in vitro and in vivo by disrupting microtubule dynamics and inducing G2/M phase cell cycle arrest and cell apoptosis. This compound exhibits robust antitumor activity and good blood-brain barrier (BBB) permeability.

  • Inhibits MARK3 and MARK4 activity
  • Suppresses glioma progression
  • Disrupts microtubule dynamics
  • Induces G2/M phase cell cycle arrest and cell apoptosis
  • Demonstrates robust antitumor activity in vivo
  • Exhibits good BBB permeability
  • Decreases Tau phosphorylation

Catalog No. 50-003-52167 Supplier Medchemexpress LLC Supplier No. HY13960450MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

PCC0208017 is a potent microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. It suppresses glioma progression both in vitro and in vivo by disrupting microtubule dynamics and inducing G2/M phase cell cycle arrest and cell apoptosis. This compound exhibits robust antitumor activity and good blood-brain barrier (BBB) permeability.

  • Inhibits MARK3 and MARK4 activity
  • Suppresses glioma progression
  • Disrupts microtubule dynamics
  • Induces G2/M phase cell cycle arrest and cell apoptosis
  • Demonstrates robust antitumor activity in vivo
  • Exhibits good BBB permeability
  • Decreases Tau phosphorylation

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.